Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

Journal Scan / Review · July 31, 2020

Rationale for CXCR2 Antagonists in Treating COVID-19

The Journal of Experimental Medicine

 

Additional Info

The Journal of Experimental Medicine
Blocking Inflammation on the Way: Rationale for CXCR2 Antagonists for the Treatment of COVID-19
J Exp Med 2020 Sep 07;217(9)e20201342, LM Koenig, DFR Boehmer, P Metzger, M Schnurr, S Endres, S Rothenfusser

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading